Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Biosyent ( (TSE:RX) ) has provided an announcement.
BioSyent’s flagship iron supplement brand FeraMAX has been named Canada’s number-one recommended over-the-counter iron supplement for the 11th consecutive year in a national survey of pharmacists and physicians. The recognition, which spans all provinces including Quebec, underscores the brand’s long-standing leadership and trusted status in the iron supplement market.
The FeraMAX Pd line, built around a patented Polydextrose-Iron Complex formulation and once-daily dosing, includes therapeutic, pediatric powder and maintenance products designed to treat, prevent and manage iron deficiency across age groups. This sustained top ranking reinforces BioSyent’s positioning in the OTC iron health segment and supports its broader strategy of marketing differentiated, clinically proven healthcare products.
The most recent analyst rating on (TSE:RX) stock is a Buy with a C$16.50 price target. To see the full list of analyst forecasts on Biosyent stock, see the TSE:RX Stock Forecast page.
Spark’s Take on RX Stock
According to Spark, TipRanks’ AI Analyst, RX is a Outperform.
The score is driven primarily by strong financial performance—high profitability and a very low-leverage balance sheet—tempered by some inconsistency in free-cash-flow conversion. Technicals are moderately supportive (positive longer-term trend but slightly soft vs. the 20-day average), and valuation is attractive with a moderate P/E and a modest dividend yield.
To see Spark’s full report on RX stock, click here.
More about Biosyent
BioSyent Inc., listed on the TSX Venture Exchange under the symbol RX, is a profitable, growth-oriented specialty healthcare company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products. The company serves healthcare professionals and patients through its Canadian pharma, international pharma and oral health business units, and has 11,499,939 common shares outstanding.
Average Trading Volume: 5,388
Technical Sentiment Signal: Buy
Current Market Cap: C$165.8M
See more data about RX stock on TipRanks’ Stock Analysis page.